134 related articles for article (PubMed ID: 29992538)
1. Use of Lipid-Lowering Drugs and the Risk of Cataract: A Population-Based Nested Case-Control Study.
Bezin J; Mansiaux Y; Noize P; Salvo F; Bégaud B; Pariente A
Clin Pharmacol Ther; 2019 Feb; 105(2):458-465. PubMed ID: 29992538
[TBL] [Abstract][Full Text] [Related]
2. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
Pariente A; Labat V; Mansiaux Y; Salvo F; Bégaud B; Raschi E; Faillie JL; Létinier L; Bezin J
Drug Saf; 2020 Aug; 43(8):767-774. PubMed ID: 32306223
[TBL] [Abstract][Full Text] [Related]
3. Risk of cataract in patients treated with statins.
Schlienger RG; Haefeli WE; Jick H; Meier CR
Arch Intern Med; 2001 Sep; 161(16):2021-6. PubMed ID: 11525705
[TBL] [Abstract][Full Text] [Related]
4. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.
Corrao G; Zambon A; Bertù L; Botteri E; Leoni O; Contiero P
J Epidemiol Community Health; 2004 Dec; 58(12):1047-51. PubMed ID: 15547071
[TBL] [Abstract][Full Text] [Related]
5. Are lipid-lowering drugs associated with a risk of cataract? A pharmacovigilance study.
Despas F; Rousseau V; Lafaurie M; De Canecaude C; Durrieu G; Bagheri H; Montastruc F; Montastruc JL
Fundam Clin Pharmacol; 2019 Dec; 33(6):695-702. PubMed ID: 31251421
[TBL] [Abstract][Full Text] [Related]
6. Association between lipid-lowering agents and severe hyponatremia: a population-based case-control study.
Skov J; Falhammar H; Calissendorff J; Lindh JD; Mannheimer B
Eur J Clin Pharmacol; 2021 May; 77(5):747-755. PubMed ID: 33215235
[TBL] [Abstract][Full Text] [Related]
7. Fibrates and risk of cancer in tissues with high PPAR-α concentration: a nested case-control study.
Salvo F; Bazin F; Kostrzewa A; Bandre C; Robinson P; Moore N; Bégaud B; Pariente A
Drug Saf; 2014 May; 37(5):361-8. PubMed ID: 24743875
[TBL] [Abstract][Full Text] [Related]
8. HMG-CoA reductase inhibitors and the risk of fractures.
Meier CR; Schlienger RG; Kraenzlin ME; Schlegel B; Jick H
JAMA; 2000 Jun; 283(24):3205-10. PubMed ID: 10866867
[TBL] [Abstract][Full Text] [Related]
9. Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase
Montastruc F; Benevent J; Rousseau V; Durrieu G; Sommet A; Montastruc JL
Fundam Clin Pharmacol; 2019 Feb; 33(1):108-112. PubMed ID: 30098074
[TBL] [Abstract][Full Text] [Related]
10. Effect of hydrophilic and lipophilic statins on early onset cataract: A nationwide case-control study.
Chen HL; Chang HM; Wu HJ; Lin YC; Chang YH; Chang YC; Lee WH; Chang CT
Regul Toxicol Pharmacol; 2021 Aug; 124():104970. PubMed ID: 34087384
[TBL] [Abstract][Full Text] [Related]
11. Statin use and risk of cataract: A nested case-control study within a healthcare database.
Casula M; Soranna D; Corrao G; Merlino L; Catapano AL; Tragni E
Atherosclerosis; 2016 Aug; 251():153-158. PubMed ID: 27323228
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis.
Choi HD; Shin WG
Curr Med Res Opin; 2014 Jan; 30(1):1-10. PubMed ID: 24063624
[TBL] [Abstract][Full Text] [Related]
13. Cataracts and statins. A disproportionality analysis using data from VigiBase.
Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
[TBL] [Abstract][Full Text] [Related]
14. Statin use and risk of first-time psoriasis diagnosis.
Brauchli YB; Jick SS; Meier CR
J Am Acad Dermatol; 2011 Jul; 65(1):77-83. PubMed ID: 21529997
[TBL] [Abstract][Full Text] [Related]
15. Statins and the risk of dementia.
Jick H; Zornberg GL; Jick SS; Seshadri S; Drachman DA
Lancet; 2000 Nov; 356(9242):1627-31. PubMed ID: 11089820
[TBL] [Abstract][Full Text] [Related]
16. Association between venous thromboembolism events and fibrates: A comparative study.
Dolladille C; Humbert X; Faucon M; Tournilhac C; Sassier M; Fedrizzi S; Milliez P; Lelong-Boulouard V; Coquerel A; Puddu PE; Parienti JJ; Alexandre J
Therapie; 2019 Jun; 74(3):421-430. PubMed ID: 30482666
[TBL] [Abstract][Full Text] [Related]
17. Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in Vigibase
Arnaud M
Fundam Clin Pharmacol; 2019 Feb; 33(1):107. PubMed ID: 30663142
[No Abstract] [Full Text] [Related]
18. Statin intolerance: diagnosis and remedies.
Pirillo A; Catapano AL
Curr Cardiol Rep; 2015 May; 17(5):27. PubMed ID: 25894795
[TBL] [Abstract][Full Text] [Related]
19. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
Koro CE; Sowell MO; Stender M; Qizilbash N
Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
[TBL] [Abstract][Full Text] [Related]
20. Statin use and risk of gallstone disease followed by cholecystectomy.
Bodmer M; Brauchli YB; Krähenbühl S; Jick SS; Meier CR
JAMA; 2009 Nov; 302(18):2001-7. PubMed ID: 19903921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
